These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9426091)

  • 21. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
    Plebani M; Basso D; Navaglia F; De Paoli M; Tommasini A; Cipriani A
    Br J Cancer; 1995 Jul; 72(1):170-3. PubMed ID: 7541234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
    Lai RS; Chen CC; Lee PC; Lu JY
    Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
    Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
    Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR; Zhang X; Xu ZF; Zheng S
    Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers in the lung cancer diagnosis: a clinical perspective.
    Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
    Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
    Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYFRA 21-1. A new marker in lung cancer.
    Stieber P; Hasholzner U; Bodenmüller H; Nagel D; Sunder-Plassmann L; Dienemann H; Meier W; Fateh-Moghadam A
    Cancer; 1993 Aug; 72(3):707-13. PubMed ID: 7687515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis.
    Pastor A; Menéndez R; Cremades MJ; Pastor V; Llopis R; Aznar J
    Eur Respir J; 1997 Mar; 10(3):603-9. PubMed ID: 9072992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.
    Barlési F; Gimenez C; Torre JP; Doddoli C; Mancini J; Greillier L; Roux F; Kleisbauer JP
    Respir Med; 2004 Apr; 98(4):357-62. PubMed ID: 15080079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
    Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of serum tumor markers in patients with lung cancer.
    Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
    Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.
    Nakamura H; Nishimura T
    Surg Today; 2017 Sep; 47(9):1037-1059. PubMed ID: 28229299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
    Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
    Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [CYFRA 21-1: a new marker of epidermoid cancer of the bronchi. Comparison with 3 other markers].
    Pujol JL; Grenier J; Ray P; Gautier V; Aouta MD; Michel FB
    Presse Med; 1993 Jun; 22(22):1039-42. PubMed ID: 7692432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer.
    Kashiwabara K; Nakamura H; Kiguchi T; Yagyu H; Kishi K; Wei BR; Yoneyama K; Matsuoka K
    Clin Chim Acta; 1997 Oct; 266(2):149-55. PubMed ID: 9437543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.